The ALS Association has launched the ALS Focus Data Dashboard, a free interactive tool that gives researchers, clinicians, and the public access to five years of self-reported clinical, demographic, and socioeconomic data from more than 4,000 people with amyotrophic lateral sclerosis (ALS) and their caregivers across the U.S.

I wish I could shake the sadness I feel as my husband Todd’s caregiver after 15 years with ALS. There’s been a cloud over our lives since his diagnosis, even when his only physical symptom was a weak arm. Living with ALS has taken a toll on both…

Researchers in the U.S. and Europe have identified a number of novel blood and spinal fluid biomarkers that could help track amyotrophic lateral sclerosis (ALS) progression and monitor patient responses to therapeutic interventions, a new study reports. Several of the proteins found altered in people with ALS versus healthy…

I’m sure we’ve entered the spooky season, a time when doing simple, normal activities feels more like a trip through the local haunted house. Goblins lurking in the shadows are ready to do their mischief. Who knew I’d find one hiding in the accessible stall of a restaurant’s restroom? But before…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CK0803, a regulatory T-cell therapy being developed by Cellenkos for amyotrophic lateral sclerosis (ALS), with a goal of slowing disease progression. The FDA designation is intended to accelerate the development and review of new treatments…